Collegium Pharmaceutical, Inc. (COLL)
| Previous Close | 37.51 |
| Open | 37.80 |
| Bid | 37.49 x 100 |
| Ask | 37.78 x 100 |
| Day's Range | 37.48 - 38.32 |
| 52 Week Range | 20.83 - 40.95 |
| Volume | |
| Avg. Volume | 422,441 |
| Market Cap | 1.231B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | 29.17 |
| EPS (TTM) | 1.29 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.00 |
ZacksCollegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksCollegium (COLL) to Report Q1 Earnings: Here's What to Expect
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
GlobeNewswireCollegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta® ER (“the Nucynta Franchise”
